We have tried a few different approaches to this trying to figure out what works best in the long run. What we’ve found is the smaller biotech companies we tend to acquire have inflated titles vs. those inside our company which has led to frustration with internal employees, especially those individuals that have long tenure and more experience than those of the acquired company. So we have shifted to re-leaving the incoming employees at the time of HR onboarding to not only put them on a level with the acquired companies employees but makes them more competitive for promotions, etc in the future. If they come in and stay at a higher title than they really are, then they become frustrated wondering why they are not getting promoted.